Cargando…
The Current Landscape of Glioblastoma Biomarkers in Body Fluids
SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain cancer, and early detection and accurate diagnosis are crucial for effective treatment. Traditional diagnostic methods have limitations, and liquid biopsies offer a non-invasive and dynamic approach to detecting and monitoring glioblastoma. T...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416862/ https://www.ncbi.nlm.nih.gov/pubmed/37568620 http://dx.doi.org/10.3390/cancers15153804 |
_version_ | 1785087878709116928 |
---|---|
author | Zanganeh, Saba Abbasgholinejad, Elham Doroudian, Mohammad Esmaelizad, Nazanin Farjadian, Fatemeh Benhabbour, Soumya Rahima |
author_facet | Zanganeh, Saba Abbasgholinejad, Elham Doroudian, Mohammad Esmaelizad, Nazanin Farjadian, Fatemeh Benhabbour, Soumya Rahima |
author_sort | Zanganeh, Saba |
collection | PubMed |
description | SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain cancer, and early detection and accurate diagnosis are crucial for effective treatment. Traditional diagnostic methods have limitations, and liquid biopsies offer a non-invasive and dynamic approach to detecting and monitoring glioblastoma. This review provides a comprehensive overview of various cancer biomarkers, including circulating tumor cells, cell-free DNA, and RNA, such as microRNA, as well as extracellular vesicles. It highlights their clinical utility in glioblastoma detection, monitoring, and prognosis. In addition, challenges and limitations in implementing liquid biopsy strategies in clinical practice are addressed. ABSTRACT: Glioblastoma (GBM) is a highly aggressive and lethal primary brain cancer that necessitates early detection and accurate diagnosis for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as imaging techniques and tissue biopsies, have limitations in providing real-time information and distinguishing treatment-related changes from tumor progression. Liquid biopsies, used to analyze biomarkers in body fluids, offer a non-invasive and dynamic approach to detecting and monitoring GBM. This article provides an overview of GBM biomarkers in body fluids, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), microRNA (miRNA), and extracellular vesicles. It explores the clinical utility of these biomarkers for GBM detection, monitoring, and prognosis. Challenges and limitations in implementing liquid biopsy strategies in clinical practice are also discussed. The article highlights the potential of liquid biopsies as valuable tools for personalized GBM management but underscores the need for standardized protocols and further research to optimize their clinical utility. |
format | Online Article Text |
id | pubmed-10416862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104168622023-08-12 The Current Landscape of Glioblastoma Biomarkers in Body Fluids Zanganeh, Saba Abbasgholinejad, Elham Doroudian, Mohammad Esmaelizad, Nazanin Farjadian, Fatemeh Benhabbour, Soumya Rahima Cancers (Basel) Review SIMPLE SUMMARY: Glioblastoma is a highly aggressive brain cancer, and early detection and accurate diagnosis are crucial for effective treatment. Traditional diagnostic methods have limitations, and liquid biopsies offer a non-invasive and dynamic approach to detecting and monitoring glioblastoma. This review provides a comprehensive overview of various cancer biomarkers, including circulating tumor cells, cell-free DNA, and RNA, such as microRNA, as well as extracellular vesicles. It highlights their clinical utility in glioblastoma detection, monitoring, and prognosis. In addition, challenges and limitations in implementing liquid biopsy strategies in clinical practice are addressed. ABSTRACT: Glioblastoma (GBM) is a highly aggressive and lethal primary brain cancer that necessitates early detection and accurate diagnosis for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as imaging techniques and tissue biopsies, have limitations in providing real-time information and distinguishing treatment-related changes from tumor progression. Liquid biopsies, used to analyze biomarkers in body fluids, offer a non-invasive and dynamic approach to detecting and monitoring GBM. This article provides an overview of GBM biomarkers in body fluids, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), microRNA (miRNA), and extracellular vesicles. It explores the clinical utility of these biomarkers for GBM detection, monitoring, and prognosis. Challenges and limitations in implementing liquid biopsy strategies in clinical practice are also discussed. The article highlights the potential of liquid biopsies as valuable tools for personalized GBM management but underscores the need for standardized protocols and further research to optimize their clinical utility. MDPI 2023-07-26 /pmc/articles/PMC10416862/ /pubmed/37568620 http://dx.doi.org/10.3390/cancers15153804 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zanganeh, Saba Abbasgholinejad, Elham Doroudian, Mohammad Esmaelizad, Nazanin Farjadian, Fatemeh Benhabbour, Soumya Rahima The Current Landscape of Glioblastoma Biomarkers in Body Fluids |
title | The Current Landscape of Glioblastoma Biomarkers in Body Fluids |
title_full | The Current Landscape of Glioblastoma Biomarkers in Body Fluids |
title_fullStr | The Current Landscape of Glioblastoma Biomarkers in Body Fluids |
title_full_unstemmed | The Current Landscape of Glioblastoma Biomarkers in Body Fluids |
title_short | The Current Landscape of Glioblastoma Biomarkers in Body Fluids |
title_sort | current landscape of glioblastoma biomarkers in body fluids |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416862/ https://www.ncbi.nlm.nih.gov/pubmed/37568620 http://dx.doi.org/10.3390/cancers15153804 |
work_keys_str_mv | AT zanganehsaba thecurrentlandscapeofglioblastomabiomarkersinbodyfluids AT abbasgholinejadelham thecurrentlandscapeofglioblastomabiomarkersinbodyfluids AT doroudianmohammad thecurrentlandscapeofglioblastomabiomarkersinbodyfluids AT esmaelizadnazanin thecurrentlandscapeofglioblastomabiomarkersinbodyfluids AT farjadianfatemeh thecurrentlandscapeofglioblastomabiomarkersinbodyfluids AT benhabboursoumyarahima thecurrentlandscapeofglioblastomabiomarkersinbodyfluids AT zanganehsaba currentlandscapeofglioblastomabiomarkersinbodyfluids AT abbasgholinejadelham currentlandscapeofglioblastomabiomarkersinbodyfluids AT doroudianmohammad currentlandscapeofglioblastomabiomarkersinbodyfluids AT esmaelizadnazanin currentlandscapeofglioblastomabiomarkersinbodyfluids AT farjadianfatemeh currentlandscapeofglioblastomabiomarkersinbodyfluids AT benhabboursoumyarahima currentlandscapeofglioblastomabiomarkersinbodyfluids |